Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae655 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Erin S LeBlanc und 3 weiteren Autor:innen. Beteiligte Einrichtung: Science Programs Department, Kaiser Permanente Center for Health Research NW, Portland, OR 97227, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Heart Disease Risk Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 144 Literaturangaben.
Abstract (Originalsprache)
Purpose
There are large disparities in the impact of diabetes on cardiovascular disease (CVD) risk and outcomes by sex and gender. Achieving health equity requires understanding risks and medication efficacy in female patients, especially now, as novel pharmacologic treatments are transforming the diabetes and CVD treatment landscape. This review examines 2 bodies of research that can inform sex differences in CVD in patients with diabetes: female-specific risk factors for CVD and sex-related limitations of clinical trial research in evaluating novel diabetes and CVD treatments.
Methods
Two literature searches were performed using Ovid Medline(R) All. The first retrieved manuscripts covering sex and gender differences related to CVD risk and therapies and diabetes. The second focused on randomized controlled trial data on sex/gender differences and GLP-1/SGLT-2/DPP-4 drugs.
Results
Female-specific risk factors for CVD include early menarche, premature or early menopause, irregular cycles and polycystic ovary syndrome; pregnancy; adverse pregnancy outcomes; history of breast cancer; and autoimmune diseases. Clinical trials of novel pharmacological treatments for diabetes and CVD have undersampled female populations, and clinical characteristics of male and female participants have differed significantly. Thus, evidence to evaluate potential sex differences in treatment efficacy and side effects has been lacking.
Conclusion
To improve health of female patients with diabetes, sex-specific cardiovascular risk factors should be taken into account in screening and treatment decisions. Further, studies of cardiovascular and diabetes medications must ensure adequate representation by sex and report participant characteristics and outcomes by sex.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Science Programs Department, Kaiser Permanente Center for Health Research NW, Portland, OR 97227, USA.
- Department of Medicine, Duke University School of Medicine, Durham, NC 27701, USA.
ORCID-Profile: Erin S LeBlanc, Ranee Chatterjee
Zitieren
APA
LeBlanc, E. S., Brooks, N., Davies, M., & Chatterjee, R. (2024). Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae655
Vancouver
LeBlanc ES, Brooks N, Davies M, Chatterjee R. Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae655
BibTeX
@article{LeBlanc2024,
author = {LeBlanc, Erin S and Brooks, Neon and Davies, Melinda and Chatterjee, Ranee},
title = {Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae655}
}
EUVIMED